täiskirje prindi

Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol

autor
kollektiivautor
ODYSSEY Outcomes Committees and Investigators
vastutusandmed
Gregory G. Schwartz, Michael Szarek, Vera A. Bittner, Rafael Diaz, Shaun G. Goodman, and on behalf of ODYSSEY Outcomes Committees and Investigators, [Margus Viigimaa et al.]
allikas
kirjastus/väljaandja
American College of Cardiology
ajakirja aastakäik number kuu
Vol. 78, 5
ilmumisaasta
leheküljed
p. 421–433 : ill
leitav
ISSN
0735-1097
keel
inglise
Uurimisrühm
Hüpertensiooni ja ateroskleroosi diagnostika ning ravi tehnoloogiate uurimisrühm
Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., ODYSSEY Outcomes Committees and Investigators, Viigimaa, M. et al. Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol // Journal of the American College of Cardiology (2021) Vol. 78, 5, p. 421–433 : ill. https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102 https://doi.org/10.1016/j.jacc.2021.04.102